메뉴 건너뛰기




Volumn 15, Issue 7-8, 2014, Pages 610-617

Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients

Author keywords

ALSFRS R; Amyotrophic lateral sclerosis; Edaravone; Placebo; Randomized trial

Indexed keywords

NORPHENAZONE; PLACEBO; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SCAVENGER;

EID: 84914677322     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2014.959024     Document Type: Article
Times cited : (288)

References (34)
  • 1
    • 0035978743 scopus 로고    scopus 로고
    • Amyotrophic lateral sclerosis
    • Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688-700.
    • (2001) N Engl J Med , vol.344 , pp. 1688-1700
    • Rowland, L.P.1    Shneider, N.A.2
  • 4
    • 0030767498 scopus 로고    scopus 로고
    • Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu/Zn superoxide disumutase mutation
    • Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu/Zn superoxide disumutase mutation. Ann Neurol. 1997;42:326-34.
    • (1997) Ann Neurol , vol.42 , pp. 326-334
    • Ferrante, R.J.1    Shinobu, L.A.2    Schulz, J.B.3    Matthews, R.T.4    Thomas, C.E.5    Kowall, N.W.6
  • 6
    • 0028971936 scopus 로고
    • Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis
    • Abe K, Pan LH, Watanabe M, Kato T, Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett. 1995;199:152-4.
    • (1995) Neurosci Lett , vol.199 , pp. 152-154
    • Abe, K.1    Pan, L.H.2    Watanabe, M.3    Kato, T.4    Itoyama, Y.5
  • 7
    • 0034623301 scopus 로고    scopus 로고
    • iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis
    • Sasaki S, Shibata N, Komori T, Iwara M. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci Lett. 2000;291: 44-8.
    • (2000) Neurosci Lett , vol.291 , pp. 44-48
    • Sasaki, S.1    Shibata, N.2    Komori, T.3    Iwara, M.4
  • 8
    • 0033009113 scopus 로고    scopus 로고
    • Remarkable increase in cerebrospinal fluid 3-nitotyrosine in patients with sporadic amyotrophic lateral sclerosis
    • Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C. Remarkable increase in cerebrospinal fluid 3-nitotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1999;46:129-31.
    • (1999) Ann Neurol , vol.46 , pp. 129-131
    • Tohgi, H.1    Abe, T.2    Yamazaki, K.3    Murata, T.4    Ishizaki, E.5    Isobe, C.6
  • 9
    • 0032953192 scopus 로고    scopus 로고
    • Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain
    • Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JM, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76-86.
    • (1999) Genes Dev , vol.13 , pp. 76-86
    • Itoh, K.1    Wakabayashi, N.2    Katoh, Y.3    Ishii, T.4    Igarashi, K.5    Engel, J.M.6
  • 10
    • 33750716074 scopus 로고    scopus 로고
    • TDP-43 is a component of ubiquitin-posive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    • Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-posive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006:351;602-11.
    • (2006) Biochem Biophys Res Commun , vol.351 , pp. 602-611
    • Arai, T.1    Hasegawa, M.2    Akiyama, H.3    Ikeda, K.4    Nonaka, T.5    Mori, H.6
  • 11
    • 33749632259 scopus 로고    scopus 로고
    • Ubiqutinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
    • Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiqutinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006:314;130-3.
    • (2006) Science , vol.314 , pp. 130-133
    • Neumann, M.1    Sampathu, D.M.2    Kwong, L.K.3    Truax, A.C.4    Micsenyi, M.C.5    Chou, T.T.6
  • 12
    • 77955423158 scopus 로고    scopus 로고
    • Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell
    • Duan W, Li X, Shi J, Guo Y, Li Z, Li C. Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience. 2010:169;1621-9.
    • (2010) Neuroscience , vol.169 , pp. 1621-1629
    • Duan, W.1    Li, X.2    Shi, J.3    Guo, Y.4    Li, Z.5    Li, C.6
  • 13
    • 0037229213 scopus 로고    scopus 로고
    • Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction
    • The Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Cerebravascuar Dis. 2003;15:222-9.
    • (2003) Cerebravascuar Dis , vol.15 , pp. 222-229
  • 14
    • 0028292964 scopus 로고
    • Protective effects of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant actions
    • Watanabe T, Yuki S, Egawa M, Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Pharmacol Exp Ther. 1994;268:1597-1604.
    • (1994) J Pharmacol Exp Ther , vol.268 , pp. 1597-1604
    • Watanabe, T.1    Yuki, S.2    Egawa, M.3    Nishi, H.4
  • 15
    • 0032054483 scopus 로고    scopus 로고
    • Inhibitory Effect of MCI-186, a free radical scavenger, on cerebral ischemia following the rat middle cerebral artery occlusion
    • Mizuno A, Umemura K, Nakashima M. Inhibitory Effect of MCI-186, a free radical scavenger, on cerebral ischemia following the rat middle cerebral artery occlusion. Gen Pharmacol. 1998;30:575-8.
    • (1998) Gen Pharmacol , vol.30 , pp. 575-578
    • Mizuno, A.1    Umemura, K.2    Nakashima, M.3
  • 16
    • 0030801031 scopus 로고    scopus 로고
    • Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia
    • Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito K, Kogure K. Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Research. 1997;762:240-2.
    • (1997) Brain Research , vol.762 , pp. 240-242
    • Yamamoto, T.1    Yuki, S.2    Watanabe, T.3    Mitsuka, M.4    Saito, K.5    Kogure, K.6
  • 18
    • 51549119688 scopus 로고    scopus 로고
    • Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice
    • Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448-55.
    • (2008) Exp Neurol , vol.213 , pp. 448-455
    • Ito, H.1    Wate, R.2    Zhang, J.3    Ohnishi, S.4    Kaneko, S.5    Ito, H.6
  • 19
    • 79952537198 scopus 로고    scopus 로고
    • Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger
    • Aoki M, Warita H, Mizuno H, Suzuki N, Yuki S, Itoyama Y. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;25:321-5.
    • (2011) Brain Res , vol.25 , pp. 321-325
    • Aoki, M.1    Warita, H.2    Mizuno, H.3    Suzuki, N.4    Yuki, S.5    Itoyama, Y.6
  • 20
    • 33847119443 scopus 로고    scopus 로고
    • Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study)
    • Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler. 2006;7:241-5.
    • (2006) Amyotroph Lateral Scler , vol.7 , pp. 241-245
    • Yoshino, H.1    Kimura, A.2
  • 21
    • 0032615390 scopus 로고    scopus 로고
    • Introduction defining optimal management in ALS: From first symptoms to announcement
    • Brooks BR. Introduction defining optimal management in ALS: from first symptoms to announcement. Neurology. 1999;53:S1-3.
    • (1999) Neurology , vol.53 , pp. S1-S3
    • Brooks, B.R.1
  • 23
    • 0032692481 scopus 로고    scopus 로고
    • The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function
    • Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169:13-21.
    • (1999) J Neurol Sci , vol.169 , pp. 13-21
    • Cedarbaum, J.M.1    Stambler, N.2    Malta, E.3    Fuller, C.4    Hilt, D.5    Thurmond, B.6
  • 24
    • 0035317343 scopus 로고    scopus 로고
    • Study of functional rating scale for amyotrophic lateral sclerosis: Revised ALSFRS (ALSFRS-R) Japanese Version
    • In Japanese
    • Ohashi Y, Tashiro K, Itoyama Y, Nakano I, Sobue G, Nakamura S, et al. Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese Version. No To Shinkei. 2001;53:346-55. (In Japanese.)
    • (2001) No to Shinkei , vol.53 , pp. 346-355
    • Ohashi, Y.1    Tashiro, K.2    Itoyama, Y.3    Nakano, I.4    Sobue, G.5    Nakamura, S.6
  • 25
    • 84914685984 scopus 로고    scopus 로고
    • [online]. Available at: Accessed November 13, 2012
    • Japan intractable diseases information center[online]. Available at: http://www.nanbyou.or.jp/entry/52. Accessed November 13, 2012.
  • 26
    • 0024792769 scopus 로고
    • A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis
    • Lacomblez L, Bouche P, Bensimon G, Meininger V. A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis. Neurology. 1989;39:1635-7.
    • (1989) Neurology , vol.39 , pp. 1635-1637
    • Lacomblez, L.1    Bouche, P.2    Bensimon, G.3    Meininger, V.4
  • 27
    • 0029857302 scopus 로고    scopus 로고
    • Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis
    • In Japanese
    • Oda E, Ohashi Y, Tashiro K, Mizuno Y, Kowa H, Yanagisawa N. Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. No To Shinkei. 1996;48:999-1007. (In Japanese.)
    • (1996) No to Shinkei , vol.48 , pp. 999-1007
    • Oda, E.1    Ohashi, Y.2    Tashiro, K.3    Mizuno, Y.4    Kowa, H.5    Yanagisawa, N.6
  • 29
    • 3843131663 scopus 로고    scopus 로고
    • Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis: Assessment questionnaire 40(ALSAQ-40)
    • In Japanese
    • Yamaguchi T, Ohbu S, Ito Y, Moriwaka F, Tashiro K, Ohashi Y, et al. Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis: Assessment questionnaire 40(ALSAQ-40). No To Shinkei. 2004;56:483-94. (In Japanese.)
    • (2004) No to Shinkei , vol.56 , pp. 483-494
    • Yamaguchi, T.1    Ohbu, S.2    Ito, Y.3    Moriwaka, F.4    Tashiro, K.5    Ohashi, Y.6
  • 30
    • 77956414915 scopus 로고    scopus 로고
    • Clinical trial for amyotrophic lateral sclerosis with free radical scavenger, edaravone
    • In Japanese
    • Yoshino H, Kimura A. Clinical trial for amyotrophic lateral sclerosis with free radical scavenger, edaravone. Neurol Therap. 2003;20:557-64. (In Japanese.)
    • (2003) Neurol Therap , vol.20 , pp. 557-564
    • Yoshino, H.1    Kimura, A.2
  • 31
    • 84862010340 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis
    • Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, et al. A randomized, double-blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PlosOne. 2012;7;6;e37885.
    • (2012) PlosOne , vol.7 , Issue.6 , pp. e37885
    • Dupuis, L.1    Dengler, R.2    Heneka, M.T.3    Meyer, T.4    Zierz, S.5    Kassubek, J.6
  • 32
    • 84856101199 scopus 로고    scopus 로고
    • The effects of dexpramipexole (KNS-76704) in individuals with amyotrophic lateral sclerosis
    • Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-76704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652-6.
    • (2011) Nat Med , vol.17 , pp. 1652-1656
    • Cudkowicz, M.1    Bozik, M.E.2    Ingersoll, E.W.3    Miller, R.4    Mitsumoto, H.5    Shefner, J.6
  • 34
    • 70449697216 scopus 로고    scopus 로고
    • Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double-blind, randomized, multicentre, placebo-controlled trial
    • Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler. 2009;10:378-83.
    • (2009) Amyotroph Lateral Scler , vol.10 , pp. 378-383
    • Meininger, V.1    Drory, V.E.2    Leigh, P.N.3    Ludolph, A.4    Robberecht, W.5    Silani, V.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.